Organon is a new company focused on women’s health. In India, Organon will be operating in women’s healthcare, fertility, dermatology, respiratory and bone health products in their portfolio. Organon India will be operating with their in-house sales force and alliance partners across the various markets.
“In India, there is a high unmet need for family planning and at the same time, as per WHO estimates, about 3.9 to 16.8 per cent of couples experience challenges in having children. As a business strategy, we will listen to women to understand their healthcare needs and find solutions which are relevant to them”, said Anjan Sen, who will lead the operations for India and countries in south Asia region.
He also added, “Our vision and mission are aligned to the Government of India’s commitment to ensure access, choice, and quality of family planning services by expanding the range and reach of contraceptive options. We will consistently make efforts to ensure availability and access to quality healthcare products for women.”
A statement from the company informed:
At launch, Organon’s portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 countries, with nearly 80 per cent of its revenue generated outside the US. Organon is well positioned for organic low-to-mid-single digit growth from its 2021 base of business, informed a company statement.
Organon in India and neighboring markets will firmly stand on its women’s health, fertility and established brands portfolio which will benefit from renewed management focus and enhanced commercial activities.
Women’s Health: Organon has a portfolio of contraceptive and fertility brands anchored by market exclusivity for ImplanonNxt (etonogestrel implant)that has long-term growth potential. In India, Organon is having 16 per cent market share in the contraception and fertility market. In the coming years, Organon will focus on scaling up its contraceptive implant ImplanonNxt thereby offering a choice of quality contraception to women in the region.
Biosimilars: Organon will be in a strong position with its current portfolio through its long-standing alliance with Samsung.
Established brands: Organon’s established brands business consists of 49 products across a range of therapeutic areas, including respiratory, cardiovascular, dermatology and non-opioid pain. The company will look to capitalise on these well-known and recognisable brands in the region.